Inge‐Britt Lindén

1.4k total citations
35 papers, 1.2k citations indexed

About

Inge‐Britt Lindén is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, Inge‐Britt Lindén has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Cellular and Molecular Neuroscience and 8 papers in Physiology. Recurrent topics in Inge‐Britt Lindén's work include Neuroscience and Neuropharmacology Research (8 papers), Parkinson's Disease Mechanisms and Treatments (6 papers) and Aldose Reductase and Taurine (4 papers). Inge‐Britt Lindén is often cited by papers focused on Neuroscience and Neuropharmacology Research (8 papers), Parkinson's Disease Mechanisms and Treatments (6 papers) and Aldose Reductase and Taurine (4 papers). Inge‐Britt Lindén collaborates with scholars based in Finland, United Kingdom and Estonia. Inge‐Britt Lindén's co-authors include Heimo Haikala, Erkki Nissinen, P Pohto, Pekka T. Männistö, Eija Schultz, Jouko Levijoki, Seppo Kaakkola, Heikki Vapaatalo, J. Parantainen and P. Kontro and has published in prestigious journals such as Free Radical Biology and Medicine, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Inge‐Britt Lindén

34 papers receiving 1.1k citations

Peers

Inge‐Britt Lindén

CCM

NEURO

CMN

PHARM

S. Kazda Germany

W. Buzello Germany

Katharina Erb Germany

Giora Davidai United States

R. Roncucci Italy

J. Taskinen Finland

Louis J. Gillespie United States

Per‐Ove Sjöquist Sweden

Kempei Matsuoka Japan

Clinton N. Corder United States

S. Kazda Germany

Inge‐Britt Lindén

452 ×1.2

CCM

400 ×1.5

235 ×1.2

NEURO

328 ×1.9

CMN

56 ×0.4

PHARM

Citations per year, relative to Inge‐Britt Lindén Inge‐Britt Lindén (= 1×) peers S. Kazda

Countries citing papers authored by Inge‐Britt Lindén

Since Specialization

Citations

This map shows the geographic impact of Inge‐Britt Lindén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge‐Britt Lindén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge‐Britt Lindén more than expected).

Fields of papers citing papers by Inge‐Britt Lindén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge‐Britt Lindén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge‐Britt Lindén. The network helps show where Inge‐Britt Lindén may publish in the future.

Co-authorship network of co-authors of Inge‐Britt Lindén

This figure shows the co-authorship network connecting the top 25 collaborators of Inge‐Britt Lindén. A scholar is included among the top collaborators of Inge‐Britt Lindén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge‐Britt Lindén. Inge‐Britt Lindén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oja, Simo S., et al.. (2009). A NEW TAURINE DERIVATIVE MY-117 WITH ANTICONVULSANT EFFECT:. Acta Neurologica Scandinavica. 65(S90). 188–189.

Haasio, Kristiina, et al.. (2001). Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. Journal of Neural Transmission. 108(1). 79–91. 30 indexed citations

Piepponen, Petteri, et al.. (1998). Conditioned Place Preference Induced by a Combination of l-Dopa and a COMT Inhibitor, Entacapone, in Rats. Pharmacology Biochemistry and Behavior. 60(1). 23–26. 16 indexed citations

Nissinen, Erkki, Petri Kaheinen, Kai E. Penttilä, Juha Kaivola, & Inge‐Britt Lindén. (1997). Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. European Journal of Pharmacology. 340(2-3). 287–294. 61 indexed citations

Haikala, Heimo, et al.. (1995). Troponin C–Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation. Journal of Cardiovascular Pharmacology. 25(5). 794–801. 187 indexed citations

Lindén, Inge‐Britt, et al.. (1995). Antioxidant properties of nitecapone are potentiated by glutathione.. PubMed. 35(2). 387–95. 10 indexed citations

Lindén, Inge‐Britt, et al.. (1992). Role of Gastric Mucosal Eicosanoid Production in the Cytoprotection Induced by Nitecapone. Scandinavian Journal of Gastroenterology. 27(2). 134–138. 11 indexed citations

Ovaska, Martti, et al.. (1992). Studies on calcium-dependent binding of simendan to troponin complex and troponin C. Journal of Molecular and Cellular Cardiology. 24. 260–260. 4 indexed citations

Raasmaja, Atso, A. Talo, Heimo Haikala, et al.. (1992). Biochemical Properties of OR-1259 - A Positive Inotropic and Vasodilatory Compound with an Antiarrhythmic Effect. Advances in experimental medicine and biology. 311. 423–423. 11 indexed citations

10.

Nissinen, Erkki, Inge‐Britt Lindén, Eija Schultz, & P Pohto. (1992). Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn-Schmiedeberg s Archives of Pharmacology. 346(3). 262–6. 117 indexed citations

11.

Honkanen, Erkki, et al.. (1989). Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. Journal of Medicinal Chemistry. 32(4). 841–846. 122 indexed citations

12.

Nissinen, Erkki, Inge‐Britt Lindén, Eija Schultz, et al.. (1988). Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. European Journal of Pharmacology. 153(2-3). 263–269. 100 indexed citations

13.

Männistö, Pekka T., Seppo Kaakkola, Erkki Nissinen, Inge‐Britt Lindén, & P Pohto. (1988). Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sciences. 43(18). 1465–1471. 54 indexed citations

14.

Lindén, Inge‐Britt, et al.. (1988). Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.. Journal of Pharmacology and Experimental Therapeutics. 247(1). 289–293. 43 indexed citations

15.

Ylitalo, Pauli, et al.. (1986). Distribution of β‐Adrenoceptor Blocking Drugs into Cerebrospinal Fluid in Rats. Acta Pharmacologica et Toxicologica. 58(1). 84–87. 5 indexed citations

16.

Andersen, Lars Peter Holst, et al.. (1984). Synthesis and Anticonvulsant Properties of Some 2-Aminoethanesulfonie Acid (Taurine) Derivatives. Journal of Pharmaceutical Sciences. 73(1). 106–108. 24 indexed citations

17.

Lindén, Inge‐Britt, G. Gothóni, P. Kontro, & Simo S. Oja. (1983). Anticonvulsant activity of 2-phthalimidoethanesulphonamides: New derivatives of taurine. Neurochemistry International. 5(3). 319–324. 24 indexed citations

18.

Lindén, Inge‐Britt. (1980). Effects of 3,4-dihydroxyphenylpyruvic acid and L-glutamic acid on some pharmacokinetic parameters of L-dopa in the rat. Journal of Pharmacy and Pharmacology. 32(1). 344–348. 7 indexed citations

19.

Lindén, Inge‐Britt, et al.. (1979). The effect of simultaneous administration of 3,4-dihydroxyphenylpyruvic acid and L-dopa on the bioavailability of L-dopa in rat and mouse. Journal of Pharmacy and Pharmacology. 31(1). 205–208. 6 indexed citations

20.

Lindén, Inge‐Britt, J. Parantainen, & Heikki Vapaatalo. (1976). Inhibition of Prostaglandin Biosynthesis by Tolfenamic Acid in Vitro. Scandinavian Journal of Rheumatology. 5(3). 129–132. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact